Post-Translational Modification Analysis
Post-translational modification analysis supporting protein characterization purity and identity confirmation through mass spectrometry and chromatographic analysis
Protein post-translational modifications (PTMs) are common to biologic drug substances produced by bioprocessing. Also known as variants, these PTM forms exhibit some degree of structural heterogeneity and are produced by the post-translational addition of a functional group covalently bonded to the protein, proteolytics cleavage or degradation. PTMs can influence the structure, stability, function and how the protein interacts.
Determining post-translational modifications such as phosphorylation, oxidation of methionine, deamidation of asparagine and glutamine, variation in glycosylation, and proteolysis can be challenging. A complex array of detailed analytics is required in order to confirm protein identity, ensure a consistent manufacturing process and product quality. Furthermore, an incorrect modification or aggregation can lead to a potentially harmful immune response in the patient or lower product efficacy.
As a PTM analysis service provider, we apply our knowledge of anticipated PTM and potential PTMs based on your product’s specific structural characteristics to design strategic analytical programs that meet the requirements of regulatory expectations and industry guidance such as ICH Q6B.
Our laboratories are equipped with a broad technology base and our strengths in mass spectrometry (Orbitrap and QToF) analysis, in particular, allow the ability to provide high-resolution, accurate-mass (HRAM) data We also apply a range of chromatographic techniques to detect and identify a range of PTMs with comparison against using against an appropriate reference standard as necessary.
Our post-translational modification experts apply a strategic approach to PTM analysis in early development phases to help you to establish product acceptance criteria for ongoing requirements or to support your process validation activities. We employ PTM analysis as part of in-depth structural characterisation studies and as a vital component of comparability programs, stability studies or quality control testing.
Post-translational modifications analysis services include studies to identify or confirm:
• Mis-matched S-S bridges
• N/C-terminal modifications e.g. C-terminal amidation
Comprehensive protein characterisation from one source
With considerable expertise in the detailed analytics required to determine post-translational modifications we provide experienced service to get you the data you need relevant to your development stage but always with an eye on your needs for later-phase development and CMC requirements such as stability testing, regulatory submissions and ongoing analysis. Bringing quality and safety to life, we offer Total Quality Assurance expertise to help you to meet and exceed quality, safety and regulatory standards.
Biopharmaceutical Analysis Services
COVID-19 VACCINE OR THERAPEUTIC TESTING & DEVELOPMENT SUPPORT
IMMEDIATE QUESTION? Ask our experts now
FACTSHEET: COVID-19 Vaccine or Therapeutic Testing & Development Outsourcing
ARTICLE: Repurposing Vaccines for Intranasal Development
WEBINAR: Quality Control Strategy for Vaccine Development
WEBINAR: Repurposing Drugs for Inhaled Delivery
eBOOK: Contingency Outsourcing Solutions
New Approaches to Bioassay Design
Characterisation of Bispecifics
The Significance and Challenges of Inhaled and Nasal Biologics
Monoclonal Antibody Characterisation - Addressing CQAs
Current Analytical Approaches to Biophysical Characterisation
Biosimilar Characterisation and Immunogenicity
GMP Flow Cytometry: Applications, Considerations and Challenges
Liposome Physicochemical Property Analysis
Formulation of Biologics for Inhaled and Nasal Delivery
The Complexities of Antibody Drug Conjugate Characterization
Download: Intertek Biopharmaceutical Services Brochure
Download: Intertek Pharmaceutical Services
Intertek Pharmaceutical Services Manchester
P.O. Box 42
Manchester, M9 8ZS
For location use: M9 8GQ
EVENT: 2nd Annual Inhaled and Nasal Biologics/DNA Forum - REGISTRATION IS LIVE
NEW VIDEO:EXTRACTABLES/LEACHABLES LAB TOUR - Request access
WORKSHOP: How to Build an Inhaler (RDD 2023)
PRESENTATION:E&L Strategies (3rd Annual Extractables & Leachables Conference)
TALK: Medical Device Extractables & Leachables Studies
TALK: ID and sensitivity issues during E&L studies
ARTICLE: Glycosylation Analytical Approaches for Antibody Therapeutics
APP NOTE: Rapid Determination of Low/Trace Level Benzene in Pharmaceutical Excipients and Finished Products
ARTICLE: Importance of Aligning a Pharma Audit Scope with the Correct Standard
TALK: mRNA Analytics: Capping Efficiency, Sequencing, Poly-A Tail, dsRNA